Repost of latest revenue potential figures - https://hotcopper.com.au/posts/42850792/single
The 3 AML pathways combined could drive a market cap of $9B ... and breast cancer $50B.
(IMO - RAC would get bought out first ... as that is what mostly happens with promising biotechs - Big Pharma just buy them out, so figures blue-sky if RAC successfully took these pathways to production)
The Breast Cancer numbers are staggering and that is essentially because RAC would be trying to take on the dominant drug used in Breast Cancer Combination chemotherapy ... which is Doxorubicin.
(see estimated capitalisation below - marked in red )
Numbers seem high but that's based on revenue and profit potential at Pharma industry margins and P/E ratios.
https://hotcopper.com.au/posts/41986789/single
For full-context, you really need to step through all the posts starting with this one as there was a bit of discussion around assumptions.
https://hotcopper.com.au/posts/41967796/single
My first attempt at a 5-path valuation was the opening post for this thread and it explains the original assumptions ( which have since evolved ).
https://hotcopper.com.au/threads/th...ncology-5-path-strategy.5078227/#.XkEugBMzZZ0
Repost of latest revenue potential figures -...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |